|
|
Volumn 11, Issue 5, 2012, Pages 337-338
|
|
Anti-NGF painkillers back on track?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANALGESIC AGENT;
FULRANUMAB;
MEDI 578;
NERVE GROWTH FACTOR ANTIBODY;
NONSTEROID ANTIINFLAMMATORY AGENT;
OPIATE;
PLACEBO;
REGN 475;
TANEZUMAB;
UNCLASSIFIED DRUG;
AVASCULAR NECROSIS;
BONE NECROSIS;
CHRONIC PAIN;
DISEASE COURSE;
DRUG DEPENDENCE;
DRUG RESEARCH;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
GASTROINTESTINAL HEMORRHAGE;
HUMAN;
INTERSTITIAL CYSTITIS;
JOINT DEGENERATION;
JOINT DESTRUCTION;
KIDNEY DISEASE;
KNEE OSTEOARTHRITIS;
LOW BACK PAIN;
NONHUMAN;
OSTEOARTHRITIS;
PAIN;
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
RISK BENEFIT ANALYSIS;
SHORT SURVEY;
ANALGESICS;
CLINICAL TRIALS AS TOPIC;
DRUG DELIVERY SYSTEMS;
DRUG DESIGN;
HUMANS;
NERVE GROWTH FACTOR;
PAIN;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84860377399
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3732 Document Type: Short Survey |
|
Times cited : (38)
|
|
References (0)
|
